|
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise.
|
 |
|
The decision is supported by results from the Phase III ECLIPSE study, which assessed Aquipta versus placebo for migraine.
|
|
|
While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.
|
|
|
Smart pharma is becoming reality. At PHARMAP 2026, industry leaders discussed the technologies transforming pharmaceutical production, supply-chain security and global healthcare delivery.
|
|
|
Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.
|
|
